BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 22, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/18 cls
Amgen (NASDAQ:AMGN) UBS Maged Shenouda Price target Neutral -5% $59.97
Shenouda raised his target to $73 from $66 after Amgen reported positive final data from the Phase III FREEDOM trial of denosumab in postmenopausal women with osteoporosis (see "Denosumab vs. Bisphosphonates," A7).
Gilead (NASDAQ:GILD) Banc of America Securities William Ho Price target Neutral -3% $46.46
Jefferies Eun Yang Price target Hold
Ladenburg Thalmann Sharon Seiler Price target Buy
Oppenheimer...

Read the full 779 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >